Teva Pharmaceutical Industries (TEVA) Competitors $17.56 -0.51 (-2.80%) Closing price 03:59 PM EasternExtended Trading$17.57 +0.02 (+0.09%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TEVA vs. TAK, ARGX, ONC, BNTX, INSM, SMMT, GMAB, ASND, VTRS, and RDYShould you be buying Teva Pharmaceutical Industries stock or one of its competitors? The main competitors of Teva Pharmaceutical Industries include Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Viatris (VTRS), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Teva Pharmaceutical Industries vs. Its Competitors Takeda Pharmaceutical argenex BeOne Medicines BioNTech Insmed Summit Therapeutics Genmab A/S Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Takeda Pharmaceutical (NYSE:TAK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment. Which has better earnings & valuation, TAK or TEVA? Takeda Pharmaceutical has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$30.09B1.61$712.33M$0.3050.68Teva Pharmaceutical Industries$16.63B1.21-$1.64B-$0.16-109.72 Do insiders & institutionals have more ownership in TAK or TEVA? 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media prefer TAK or TEVA? In the previous week, Teva Pharmaceutical Industries had 10 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 4 mentions for Takeda Pharmaceutical. Teva Pharmaceutical Industries' average media sentiment score of 1.56 beat Takeda Pharmaceutical's score of 1.20 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 13 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk and volatility, TAK or TEVA? Takeda Pharmaceutical has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Is TAK or TEVA more profitable? Takeda Pharmaceutical has a net margin of 3.20% compared to Teva Pharmaceutical Industries' net margin of -0.95%. Teva Pharmaceutical Industries' return on equity of 46.10% beat Takeda Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical3.20% 10.50% 5.10% Teva Pharmaceutical Industries -0.95%46.10%7.18% Do analysts rate TAK or TEVA? Teva Pharmaceutical Industries has a consensus target price of $24.71, suggesting a potential upside of 40.78%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Is TAK or TEVA a better dividend stock? Takeda Pharmaceutical pays an annual dividend of $0.55 per share and has a dividend yield of 3.6%. Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 5.8%. Takeda Pharmaceutical pays out 183.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Teva Pharmaceutical Industries pays out -631.9% of its earnings in the form of a dividend. Teva Pharmaceutical Industries is clearly the better dividend stock, given its higher yield and lower payout ratio. SummaryTeva Pharmaceutical Industries beats Takeda Pharmaceutical on 13 of the 19 factors compared between the two stocks. Get Teva Pharmaceutical Industries News Delivered to You Automatically Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TEVA vs. The Competition Export to ExcelMetricTeva Pharmaceutical IndustriesMED IndustryMedical SectorNYSE ExchangeMarket Cap$20.13B$4.00B$5.76B$20.87BDividend YieldN/A1.23%3.91%3.59%P/E Ratio-109.7211.0430.7828.34Price / Sales1.2111.76457.7654.34Price / Cash5.317.2725.2217.82Price / Book3.703.169.364.54Net Income-$1.64B-$109.62M$3.26B$992.74M7 Day Performance5.88%5.08%1.84%0.29%1 Month Performance9.17%23.52%3.69%1.13%1 Year Performance-3.99%33.58%28.89%11.00% Teva Pharmaceutical Industries Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TEVATeva Pharmaceutical Industries3.5997 of 5 stars$17.56-2.8%$24.71+40.8%-1.0%$20.13B$16.63B-109.7236,830News CoveragePositive NewsTAKTakeda Pharmaceutical1.3412 of 5 stars$14.43-0.1%N/A+4.7%$45.90B$30.09B48.0847,455News CoveragePositive NewsShort Interest ↑ARGXargenex3.9645 of 5 stars$638.90-3.5%$746.81+16.9%+26.0%$39.10B$2.25B32.761,599Positive NewsONCBeOne Medicines0.6443 of 5 stars$289.75+0.5%$330.89+14.2%N/A$31.76B$4.56B-167.4811,000BNTXBioNTech1.6248 of 5 stars$109.26-2.1%$135.91+24.4%+32.1%$26.27B$2.98B-68.296,772Analyst RevisionINSMInsmed4.0992 of 5 stars$112.89+3.0%$112.71-0.2%+67.0%$21.42B$398.11M-19.771,271SMMTSummit Therapeutics2.3402 of 5 stars$28.25-1.4%$34.67+22.7%+126.6%$20.98BN/A-83.09110News CoverageAnalyst DowngradeGap DownGMABGenmab A/S3.8673 of 5 stars$21.08-1.6%$37.80+79.3%-13.1%$13.52B$3.26B10.592,682Positive NewsAnalyst RevisionASNDAscendis Pharma A/S2.0562 of 5 stars$195.97+2.3%$239.80+22.4%+39.8%$11.98B$393.54M-37.981,017Analyst ForecastVTRSViatris2.0336 of 5 stars$9.86+1.6%$10.40+5.5%-8.8%$11.57B$14.74B-3.4032,000RDYDr. Reddy's Laboratories2.8344 of 5 stars$13.81+0.0%$16.95+22.8%-12.8%$11.53B$334.26B20.9227,811News Coverage Related Companies and Tools Related Companies TAK Alternatives ARGX Alternatives ONC Alternatives BNTX Alternatives INSM Alternatives SMMT Alternatives GMAB Alternatives ASND Alternatives VTRS Alternatives RDY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:TEVA) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access